# Improving the diagnostic strategy of patients with recurrent differentiated thyroid cancer with PET/CT.

No registrations found.

Ethical review	Positive opinion
Status	Suspended
Health condition type	-
Study type	Observational non invasive

## **Summary**

### ID

NL-OMON27626

**Source** Nationaal Trial Register

**Brief title** THYROPET

#### **Health condition**

Differentiated thyroid cancer I-124 PET/CT FDG PET/CT

## **Sponsors and support**

**Primary sponsor:** The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital **Source(s) of monetary or material Support:** KWF - The Dutch Cancer Society

## Intervention

#### **Outcome measures**

#### **Primary outcome**

The number of futile high-dose 1311 treatments that could have been avoided by

1 - Improving the diagnostic strategy of patients with recurrent differentiated thyr  $\ldots$  14-05-2025

implementation of pre-therapy imaging based on result of post-therapy scintigraphy.

#### Secondary outcome

- 1. Synchronised QA/QC of 124I-PET in the Netherlands;
- 2. Correlations of 124I-PET and FDG-PET with histopathological parameters and Tg;
- 3. Correlation between 124I-PET findings during rhTSH and withdrawal combined with LID.

# **Study description**

#### **Background summary**

After initial treatment of DTC patients are followed biochemically by thyroglobulin to detect possible recurrence. Nowadays patients are treated blindly with high dose 1311. When recurrence is suspected a whole body scintigraphy is made, after blind administration of high dose, 'therapeutic', 1311 to diagnose and treat recurrence and metastatic disease. In up to 50% this strategy can considered to be futile because they had a negative post-therapeutic whole body scan and/or no objective therapy effect. 1241 in combination with whole body PET became recently available for use in the follow-up of DTC. This could make it possible to more accurately re-stage patients in a whole body procedure, perform dosimetry for subsequent 1311 therapy and predict the outcome of the treatment before the actual treatment with 1311. Additionally, recurrent DTC lesions that do not accumulate iodine can be re-staged without the futile treatment with 1311. FDG-PET is able to detect these lesions. The value of FDG-PET before 1311 treatment however has not been tested.

The combination of these two diagnostic tools, 124I-PET and FDG-PET, has a potential to allow earlier and better restaging and selection for treatment.

The objective is to evaluate the value of combined imaging with 124I-PET and FDG PET in the prevention of futile treatment with high dose 131I.

Multicenter prospective observational cohort study.

#### Study objective

N/A

#### Study design

2 - Improving the diagnostic strategy of patients with recurrent differentiated thyr ... 14-05-2025

#### Intervention

A combination of I-124 PET/CT and FDG PET/CT to firstly detect the recurrence and secondly assess its biological behavior.

# Contacts

**Public** Huispost nummer G04.228<br> UMC Utrecht <br> Postbus 85500 J.W. Kist Utrecht 3508 GA The Netherlands +31 (0)6 41853004 Scientific Huispost nummer G04.228<br> UMC Utrecht <br> Postbus 85500 J.W. Kist Utrecht 3508 GA The Netherlands +31 (0)6 41853004

## **Eligibility criteria**

## **Inclusion criteria**

- 1. Patients with a history of differentiated thyroid cancer;
- 2. After complete thyroidectomy and ablation of functional remnants with 131I;
- 3. Planned for blind high dose 131I treatment based on biochemically suspected recurrence, defined as a Tg-level above 2.0 ng/ml;
- 4. Ultrasonography of the neck performed < 2 months prior to inclusion.

## **Exclusion criteria**

- 1. Age < 18 years;
- 2. Pregnancy;
- 3. Incapacitated subjects;
- 4. Contrast enhanced CT performed < 4 months prior to inclusion;
- 5. I-131 therapy performed < 12 months prior to inclusion;

6. Indication for other therapy modality (ie. surgery in case of a positive ultrasonography, radiotherapy, embolization or chemotherapy).

# Study design

## Design

Study type:	Observational non invasive
Intervention model:	Parallel
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

## Recruitment

NL	
Recruitment status:	Suspended
Start date (anticipated):	01-09-2012
Enrollment:	100
Туре:	Anticipated

# **Ethics review**

Positive opinion Date:

10-07-2012

# **Study registrations**

## Followed up by the following (possibly more current) registration

ID: 38034 Bron: ToetsingOnline Titel:

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL3371
NTR-old	NTR3519
ССМО	NL37266.031.11
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON38034

# **Study results**

Summary results N/A